TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24946636
Drug: Metformin hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin hydrochloride tablet (0.5 g, once a day for the first week, twice a day from the second week)
Study: 8026259
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg on weekends (group B)
Study: 18808445
Drug: Naloxone-3-glucuronide (NX3G)
Normalized name: MENTHOL GLUCURONIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone-3-glucuronide (NX3G) 0.16 mg/kg
Study: 31067138
Drug: Local Consolidative
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local Consolidative Therapy (LCT)
Study: 31067138
Drug: Maintenance Therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance Therapy or Observation (MT/O)
Study: 30995611
Drug: Half and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half and quarter doses
Study: 8110568
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% 40 ml with morphine 2 mg (group BM2)
Study: 9387133
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rhEPO) given intravenously for 8 weeks at 50 Ul/kg body weight three times a week, then subcutaneously for 4 weeks at 25 Ul/kg body weight twice a week, and for the last 8 weeks at 25 Ul/kg body weight once a week.
Study: 16532455
Drug: Gabapentin treatment
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin treatment
Study: 14551096
Drug: Compliance therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compliance therapy
Study: 6453571
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy
Study: 24809976
Drug: Volume-controlled ventilation
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Volume-controlled ventilation with VT 10 ml/kg predicted body weight
Study: 12947360
Drug: Cholesterol-lowering medication
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-lowering medication
Study: 20118170
Drug: Patient engagement
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient engagement in treatment decisions
Study: 20118170
Drug: Awareness of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Awareness of medication requests
Study: 20118170
Drug: Patient inquiries
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient inquiries about medication
Study: 8699068
Drug: SPf66 synthetic
Normalized name: Camphor (synthetic)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPf66 synthetic vaccine
Study: 22633322
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine
Study: 23413812
Drug: Commercially pure
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially pure titanium narrow diameter implants
Study: 23413812
Drug: Titanium-zirconium alloy
Normalized name: zirconium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titanium-zirconium alloy narrow diameter implants
Study: 9806503
Drug: Concurrent ChT
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent ChT and hyperfractionated RT (69.6 Gy in 6 weeks)
Study: 17203523
Drug: Comprehensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive treatment (Shehuang Paste + Chinese herbal colon dialysis)
Study: 17203523
Drug: Simple treatment
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple treatment (Shehuang Paste only)
Study: 27088471
Drug: Functional Electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional Electrical Stimulation (FES) cycling training for 15 days (30 minutes daily for 5 days a week)
Study: 29743598
Drug: Urinary protein
Normalized name: Urinary protein of low molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary protein excretion (≥ 3.5 g/d)
Study: 15342612
Drug: Curative ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Curative ibuprofen (same dosage regimen as prophylactic)
Study: 8299455
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin injected subcutaneously in the abdomen
Study: 10593347
Drug: US 3
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: US 3 G: 1 g of stanol (ester form) per 8‐g serving of a US reformulation 3 times a day
Study: 28527420
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) followed by surgery with or without radiotherapy.
Study: 8525777
Drug: Subunit influenza
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subunit influenza vaccine (15 micrograms of each haemagglutinin strain)
Study: 9735587
Drug: Delayed-treatment control
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-treatment control
Study: 27603424
Drug: Alternating therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating therapy with MMC and BCG
Study: 10202830
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate 195 mg weekly
Study: 12841885
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen (50 microg/day) and medroxyprogesterone acetate (5 mg/day) continuously
Study: 29973224
Drug: Iron isomaltoside
Normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron isomaltoside 1000 (IVFe) administered intravenously 1000 mg (maximum dose 20 mg/kg) 3 days before and after surgery
Study: 15804075
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (Control)
Study: 19906075
Drug: Alitretinoin 10
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alitretinoin 10 mg once daily for 12-24 weeks
Study: 10539123
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir (5 mg/kg/day)
Study: 1743712
Drug: Podophyllin resin
Normalized name: podophyllin
DrugBank: Podophyllin (DB09094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Podophyllin resin 25% applied to lesions twice weekly for up to six weeks
Study: 6107725
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg DAMME (FK33-824, Sandoz) infusion
Study: 7135
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg
Study: 16154480
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg OD (V160)
Study: 16154480
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg OD plus Hydrochlorothiazide 12.5 mg OD (V160 + HCTZ12.5)
Study: 2265733
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion pump therapy (CSII)
Study: 27159624
Drug: Group M
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group M (0.05 mg/kg midazolam)
Study: 7746058
Drug: Simvastatin therapy
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin therapy
Study: 8986917
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg once a day
Study: 1335643
Drug: Vaccine-induced antibodies
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine-induced antibodies after booster dose
Study: 20560291
Drug: Inhaled iloprost
Normalized name: iloprost Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled iloprost (5 mcg every 2-3 hours while awake)
Study: 7635769
Drug: Stage IIB
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage IIB treatment duration < 55 days
Study: 8339809
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 1 mg/day
Study: 8339809
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate 2 mg/day
Study: 18509786
Drug: Pharmacological closure
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological closure (NSAIDs treatment)
Study: 22515886
Drug: 1.9 mL
Normalized name: 1.9 ML Elrexfio 40 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.9 mL of lidocaine (76.4 mg) with epinephrine plus 0.5 mol/L mannitol
Study: 28947725
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy accompanied by oral anticoagulation (OAC) - triple therapy
Study: 20101008
Drug: Orlistat therapy
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat therapy plus low-fat diet (O + LFD)
Study: 15867009
Drug: Intramuscular testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular testosterone enanthate (100 mg weekly) plus oral levonorgestrel (31.25 microg daily)
Study: 6833466
Drug: Dermorphin during
Normalized name: Pro-C-Dure 6 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermorphin during naloxone infusion
Study: 2797920
Drug: Pressurized aerosol
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pressurized aerosol (2 mg terbutaline)
Study: 29492934
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg
Study: 26874901
Drug: Neratinib 240
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neratinib 240 mg per day
Study: 17684876
Drug: Granisetron 1
Normalized name: granisetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 1 mg plus Droperidol 1.25 mg
Study: 17684876
Drug: Granisetron 1
Normalized name: granisetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 1 mg plus Dexamethasone 8 mg
Study: 22440125
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in urinary albumin excretion (UAE) of 2 logs at 1 year
Study: 22306735
Drug: Hormone receptor-positive
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone receptor-positive disease
Study: 1575174
Drug: Nifedipine SR
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine SR 20 mg
Study: 18094220
Drug: clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: clarithromycin 500 mg bid
Study: 11397620
Drug: ofloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ofloxacin 400 mg bid
Study: 9310602
Drug: Weekly Deltaprim
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly Deltaprim (malaria prophylaxis)
Study: 18008241
Drug: Monthly IPTp
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly IPTp (sulfadoxine-pyrimethamine)
Study: 8576675
Drug: Clinacanthus nutans
Normalized name: Streptococcus mutans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinacanthus nutans extract applied five times daily for 7-14 days
Study: 31399915
Drug: Early combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early combination therapy with gentamicin (treatment started within 48 hours of culture results and continued for a minimum of 7 days)
Study: 28686664
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose of hydrocortisone (0.2-0.3 mg HC/kg body weight/day)
Study: 28686664
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of hydrocortisone (0.4-0.6 mg HC/kg body weight/day)
Study: 23374199
Drug: Strain-counterstrain treatment
Normalized name: Haemagglutinin-strain B
DrugBank: Haemagglutinin-strain B (DB15482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strain-counterstrain treatment after full osteopathic treatment
Study: 21675956
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy using plasmidial constructs expressing vascular endothelial and hepatocyte growth factors
Study: 26086603
Drug: High loading
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High loading dose of Rosuvastatin before PCI
Study: 17978591
Drug: Metoprolol tartrate
Normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol tartrate 50 to 200 mg bid
Study: 19773619
Drug: Bone cement
Normalized name: bone cement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone cement augmentation (Group 1, n=12)
Study: 3391878
Drug: Erythromycin acistrate
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin acistrate (EA) 500 mg tid for three days
Study: 3391878
Drug: Erythromycin base
Normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin base (EB) enterotablets 500 mg tid for three days
Study: 15336467
Drug: Immediate-release oxybutynin
Normalized name: oxybutynin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release oxybutynin (TID)
Study: 11876710
Drug: Post-drug withdrawal
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-drug withdrawal
Study: 3391878
Drug: Erythromycin base
Normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin base (EB) enterocapsules 500 mg tid for three days
Study: 3391878
Drug: Erythromycin stearate
Normalized name: Erythromycin Stearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin stearate (ES) 500 mg tid for three days
Study: 9632571
Drug: Cellular vaccine
Normalized name: PERTUSSIS VACCINE,ACELLULAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellular vaccine
Study: 28489468
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate (BD) ¼ dilution (1.25 mg/dL)
Study: 16417774
Drug: Fenbid Capsules
Normalized name: fenbid
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fenbid Capsules 0.3 g twice a day and Tripterygium tablet 20 mg thrice a day for 6 weeks
Study: 21671456
Drug: Dronabinol 20
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dronabinol 20 mg
Study: 26483357
Drug: Dronabinol 30
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dronabinol 30 mg
Study: 21671456
Drug: Dronabinol 40
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dronabinol 40 mg
Study: 26483357
Drug: Dronabinol 5
Normalized name: dronabinol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol 5 mg
Study: 8858268
Drug: Cilazapril 2.5
Normalized name: cilazapril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 2.5 mg daily
Study: 22867539
Drug: Paracetamol 1
Normalized name: Paracetamol 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1 g and ketorolac 20 mg intravenously
Study: 3122628
Drug: TTS NG
Normalized name: NG
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTS NG 10 mg/24 h
Study: 1643799
Drug: Porcine Insulin
Normalized name: Porcine insulin
DrugBank: Insulin pork (DB00071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine Insulin (PI)
Study: 12095665
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of oral cocaine HCl
Study: 2003340
Drug: Intravenous ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ofloxacin
Study: 27681702
Drug: Rivastigmine patch
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine patch (5 cm2 [4.6 mg/24 h], 10 cm2 [9.5 mg/24 h], 15 cm2 [13.3 mg/24 h], and 20 cm2 [17.4 mg/24 h])
Study: 23445266
Drug: Intercostal nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intercostal nerve blockade with 20 mL of 0.5% bupivacaine with epinephrine
Study: 16979453
Drug: Patient phone
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient phone call to assess smoking status, quit challenges, and treatment preferences, and computerized progress note to providers communicating this information
Study: 2498074
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) suspension administered orally after an overnight fast
Study: 16511917
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cyclosporine (CSA) and leflunomide (LEF)
Study: 3753754
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of 1,25(OH)2D3 treatment in five children
Study: 16842480
Drug: Nateglinide plus
Normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nateglinide plus metformin
Study: 16842480
Drug: Gliclazide plus
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide plus metformin
Study: 11453888
Drug: Dihydrocodeine (DHC)
Normalized name: chlorpheniramine / dihydrocodeine / phenylephrine Oral Solution [Tusscough DHC]
DrugBank: Dihydrocodeine (DB01551)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dihydrocodeine (DHC) 90 mg
Study: 25047245
Drug: Problem-Solving Treatment
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-Solving Treatment
Study: 11070746
Drug: Zafirlukast ('Accolate')
Normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zafirlukast ('Accolate') 20 mg twice daily
Study: 31706582
Drug: Hydrocortisone administration
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone administration
Study: 24806747
Drug: Niaspan(®) (2 g/day)
Normalized name: Niaspan
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niaspan(®) (2 g/day)
Study: 1092444
Drug: Prophylactic antibiotic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotic therapy initiated preoperatively, with moderately high dosage for short periods.
Study: 27984024
Drug: Topical antibiotics
Normalized name: Tetracycline and derivatives, topical antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antibiotics
Study: 21897336
Drug: Alcohol infusions
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol infusions combined with initial oral alcohol load up to a blood alcohol steady state of 100 mg/dL (healthy volunteers, n = 12)
Study: 18452779
Drug: Conventional calcium-channel
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional calcium-channel blocker (CCB) therapy
Study: 15378145
Drug: Colchicine administered
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine administered as a single daily dose (Group II)
Study: 91023
Drug: A combination
Normalized name: Enema combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: A combination of 50 mg acarbose and 14.5 g guar gum
Study: 19029093
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg kg(‐1) bolus
Study: 26929616
Drug: Telephone-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-delivered cognitive behavior therapy (CBT)
Study: 23706546
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (placebo)
Study: 21316535
Drug: MF59-adjuvanted H5N1
Normalized name: Influenza A monovalent (H5N1), ADJUVANTED-2013
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted H5N1 influenza vaccine (7.5-μg doses) with a 2-week interval
Study: 21316535
Drug: MF59-adjuvanted H5N1
Normalized name: Influenza A monovalent (H5N1), ADJUVANTED-2013
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted H5N1 influenza vaccine (7.5-μg doses) with a 3-week interval
Study: 8150016
Drug: Medium-titre Edmonston-Zagreb
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-titre Edmonston-Zagreb (EZ) measles vaccine (10(4.6) p.f.u.)